Description
How It Works
BPC-157 is a synthetic pentadecapeptide derived from a protein fragment associated with gastric juice. It has been studied for its effects on soft-tissue recovery, angiogenic signalling, cellular migration, and GI repair pathways. Preclinical work has explored its role in tendon, ligament, muscle, and gut models, which is why it is commonly positioned around recovery and tissue-support protocols. Human evidence remains limited, so it is best presented as an investigational recovery-focused peptide rather than a fully established clinical therapy. :contentReference[oaicite:1]{index=1}
| Pathway |
Primary Effect |
| Soft-tissue signalling |
Studied for tendon, ligament, and muscle recovery support |
| Cell migration and repair |
Explored for tissue repair and structural recovery pathways |
| GI support |
Studied for gut integrity and GI healing models |
| Recovery support |
Used where the goal is tissue resilience and recovery progression |
Results and Outcomes
BPC-157 is most commonly used where the goal is support for tendon and ligament recovery, soft-tissue healing, injury recovery, and gut-focused repair. Preclinical literature is strongest in musculoskeletal and gastrointestinal models, while human evidence remains sparse. That makes it suitable for a measured recovery-support position rather than exaggerated performance claims. :contentReference[oaicite:2]{index=2}
| Expected Outcome |
Practical Effect |
| Tendon and ligament support |
Used where the goal is improved soft-tissue recovery |
| Acute injury support |
Used in more intensive short-term recovery protocols |
| Gut support |
Used in GI-focused recovery and healing protocols |
| Soft-tissue resilience |
Supports broader recovery-focused protocols over time |
Suggested Dosage Table
| Units |
Dose |
Volume |
| 10 units |
0.25 mg |
0.10 mL |
| 20 units |
0.50 mg |
0.20 mL |
| 30 units |
0.75 mg |
0.30 mL |
| 40 units |
1.00 mg |
0.40 mL |
Recommended Dosage
| Use Case |
Dose |
Frequency |
Pen Equivalent |
| Tendon & Ligament support |
0.25 mg |
2x per day |
10 units per dose |
| Acute injury treatment |
0.30–0.50 mg |
2x per day |
12–20 units per dose |
| Gut health & GI healing |
0.50–0.75 mg |
1–2x per day on an empty stomach |
20–30 units per dose |
Protocol Notes
| Guidance |
Detail |
| Shorter recovery cycles |
Typical use runs 4–8 weeks |
| Chronic injury support |
Longer protocols may extend up to 12 weeks |
| Gut-focused use |
Use on an empty stomach when following GI support protocols |
| Format |
Ready-to-use cartridge with no mixing required |
Warnings
| Warning |
Detail |
| Storage |
Keep refrigerated |
| Cycle duration |
Use shorter cycles first, then extend only where needed |
| GI timing |
For gut-focused use, dose on an empty stomach |
Related Products
| Product |
Use Case |
| TB-500 |
Recovery-focused pairing |
| GHK-Cu |
Skin and repair-focused pairing |
| KPV |
Gut and inflammation-focused pairing |
| Reusable Pen Kit |
Required for cartridge-based use |